Physician profile
Ly Tran
NPI 1790541068
$2,198.89
in general payments reported to CMS, 2019-2025
24 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $402 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.84 | 2024-2025 | |
| Amgen INC. | $389.22 | 2024-2025 | Otezla, Enbrel, Krystexxa |
| Pfizer INC. | $196.18 | 2025 | |
| Mallinckrodt Hospital Products INC. | $171.83 | 2025 | Acthar |
| Ucb, INC. | $134.81 | 2024-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $100.27 | 2024-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $93.26 | 2025 | |
| Ani Pharmaceuticals, INC. | $84.95 | 2025 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $81.33 | 2024-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $60.28 | 2024-2025 | Lupkynis |
| Csl Behring | $55.31 | 2024 | Haegarda, Hizentra |
| Sobi, INC | $54.44 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.15 | 2024 | Hyqvia, Takhzyro |
| Radius Health, INC. | $47.82 | 2025 | Tymlos |
| Biocryst US Sales Co., LLC | $41.16 | 2024 | Orladeyo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.64 | 2025 | Sotyktu, Orencia |
| Grifols USA, LLC | $35.36 | 2024 | Xembify |
| Sandoz INC. | $33.13 | 2025 | Hyrimoz |
| Lilly USA, LLC | $26.94 | 2025 | Taltz |
| Biocon Biologics INC | $25.59 | 2025 | Yesintek |
| Tersera Therapeutics LLC | $22.05 | 2024 | Quzyttir |
| Fresenius Kabi USA, LLC | $21.77 | 2025 | |
| Pharming Healthcare, INC. | $17.41 | 2024 | Ruconest |
| Glaxosmithkline, LLC. | $16.15 | 2025 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ly Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.